“The current scenario has exposed some structural weaknesses inside the EU’s medicines supply chain and a high dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She proposed that provide chain issues be dealt with in an EU pharmaceutical tactic expected to generally be released by the end with the year.